What a Trial Assistant Actually Owns

Part of Clinical Trial Assistant (CTA) Training: Foundations for the Trial Assistant.

About 5 minutes. Free, in your language, no account needed.

Why this matters

The Clinical Trial Assistant is the role most often described by what it is not. Not the coordinator, not the monitor, not the project manager. That framing is useless on your first day, and it is wrong.

The CTA owns a specific and defensible set of things: the completeness of the trial record, the movement of documents between sponsor, site and vendor, and the readiness of the study to be looked at by someone with authority. Nobody else in the trial owns those end to end.

ICH E6(R3) never uses the words "trial assistant". It describes duties, and it assigns them to the sponsor or the investigator. What your job actually is, in regulatory terms, is executing a portion of the sponsor's duties under delegation. That is worth understanding precisely, because it tells you where your judgment is required and where it is not.

The three things you own

The record is complete and current. Under E6(R3) the sponsor must maintain essential documents that permit the evaluation of the conduct of a trial and the quality of the data produced. In practice somebody has to know, today, which documents exist, which are missing, and which are out of date. That is usually you. A trial master file is not a filing cabinet; it is the evidence that the trial happened the way the protocol said it would.

Things move, and they arrive. A safety letter that was sent but never acknowledged has not been distributed. A shipment that left the depot but sat at customs has not been delivered. Your job is not to push things out; it is to confirm they landed.

The study can be inspected without a scramble. Inspection readiness is not an activity that happens before an inspection. It is the state a well-run study is in continuously. If a fourteen-day notice causes panic, the work was not being done.

What you do not own, and must not pretend to

You do not make eligibility decisions. You do not assess causality on an adverse event. You do not decide whether a protocol deviation is reportable. You do not consent participants.

This is not a hierarchy point, it is a regulatory one. E6(R3) places those duties with the investigator, and the investigator cannot delegate a duty to someone not qualified to perform it. When you are asked to do one of them, the correct answer is to route it, quickly and to the right person, and to record that you did.

The most common way a competent CTA gets a study into trouble is by being helpful past the edge of the role. "I'll just file it as a note to file" is where that starts.

Where the role sits

You typically report into a study or project manager and work alongside coordinators at sites and monitors in the field. You are frequently the only person who sees the whole document set at once. That gives you a view nobody else has, and it is why escalation from a CTA is taken seriously: if you say a site file is incomplete, you are usually right, because you are the only one who looked.

In practice

Priya is the trial assistant on a six-country study. On a Tuesday she receives three things: a coordinator in Nairobi asking whether a participant who missed a visit window can still be dosed, a courier notification that a shipment to Pune cleared customs, and an ethics approval letter for an amendment at a site in Lisbon.

Only one of those is hers to decide, and it is not the interesting one.

The dosing question is an eligibility and protocol judgment. It belongs to the investigator, and the correct action is to route it within the hour to the site's investigator and the medical monitor, say plainly that she is doing so, and record the time. Answering it herself, even correctly, would be a delegated task performed by someone not delegated to perform it.

The shipment notification needs confirmation, not acknowledgement. Cleared customs is not delivered, and delivered is not received. She will not close it until the site confirms receipt, quantity, condition and temperature.

The approval letter is entirely hers. It goes into the file today, the previous version is marked superseded, the effective date is recorded, and she checks whether anything downstream depends on it: does the consent form change, does training need to happen, does supply need adjusting.

By Friday the study has one documented escalation, one confirmed delivery and one properly propagated amendment. None of it was dramatic, and all three would have been visible as failures a year later.

What this looks like when it goes wrong

The same Tuesday, handled by someone being helpful, produces a different file. The dosing question is answered by email with a reasonable-sounding judgment, which is now an undocumented protocol decision made by an undelegated person. The shipment is marked delivered on the courier's notification, and three weeks later nobody can prove the product was ever received in condition. The approval letter is filed correctly and nothing downstream is checked, so the site runs the new protocol against the old consent form.

Every one of those is recoverable if caught in a week and expensive if caught at inspection.

Key takeaways